These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 26833058)

  • 21. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.
    Roubtsova A; Munkonda MN; Awan Z; Marcinkiewicz J; Chamberland A; Lazure C; Cianflone K; Seidah NG; Prat A
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):785-91. PubMed ID: 21273557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
    Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A
    Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.
    Yan H; Ma YL; Gui YZ; Wang SM; Wang XB; Gao F; Wang YP
    Acta Pharmacol Sin; 2014 Aug; 35(8):994-1004. PubMed ID: 25042549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells.
    Lan H; Pang L; Smith MM; Levitan D; Ding W; Liu L; Shan L; Shah VV; Laverty M; Arreaza G; Zhang Q; Murgolo NJ; Hernandez M; Greene JR; Gustafson EL; Bayne ML; Davis HR; Hedrick JA
    J Cell Physiol; 2010 Jul; 224(1):273-81. PubMed ID: 20333646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.
    Butkinaree C; Canuel M; Essalmani R; Poirier S; Benjannet S; Asselin MC; Roubtsova A; Hamelin J; Marcinkiewicz J; Chamberland A; Guillemot J; Mayer G; Sisodia SS; Jacob Y; Prat A; Seidah NG
    J Biol Chem; 2015 Jul; 290(30):18609-20. PubMed ID: 26085104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F; Park J; Redemann N; Luippold G; Nar H
    J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polydatin ameliorates low-density lipoprotein cholesterol and lipid metabolism by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in triple-negative breast cancer with hyperlipidemia.
    Liu M; Zhang Q
    Am J Cancer Res; 2024; 14(1):52-72. PubMed ID: 38323270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
    Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
    PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
    Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
    Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
    Le QT; Blanchet M; Seidah NG; Labonté P
    J Biol Chem; 2015 Sep; 290(38):23385-400. PubMed ID: 26195630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
    Kourimate S; Le May C; Langhi C; Jarnoux AL; Ouguerram K; Zaïr Y; Nguyen P; Krempf M; Cariou B; Costet P
    J Biol Chem; 2008 Apr; 283(15):9666-73. PubMed ID: 18245819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH.
    Lo Surdo P; Bottomley MJ; Calzetta A; Settembre EC; Cirillo A; Pandit S; Ni YG; Hubbard B; Sitlani A; Carfí A
    EMBO Rep; 2011 Dec; 12(12):1300-5. PubMed ID: 22081141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
    Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
    Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proprotein convertase subtilisin/kexin 9 inhibitor downregulates microRNA-130a-3p expression in hepatocytes to alleviates atherosclerosis progression.
    Xu J; Zuo J; Han C; Li T; Jin D; Zhao F; Cong H
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1727-1736. PubMed ID: 37721554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
    Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Affinity and kinetics of proprotein convertase subtilisin/kexin type 9 binding to low-density lipoprotein receptors on HepG2 cells.
    Mousavi SA; Berge KE; Berg T; Leren TP
    FEBS J; 2011 Aug; 278(16):2938-50. PubMed ID: 21692990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor.
    Zhang Y; Eigenbrot C; Zhou L; Shia S; Li W; Quan C; Tom J; Moran P; Di Lello P; Skelton NJ; Kong-Beltran M; Peterson A; Kirchhofer D
    J Biol Chem; 2014 Jan; 289(2):942-55. PubMed ID: 24225950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells.
    Levy E; Ben Djoudi Ouadda A; Spahis S; Sane AT; Garofalo C; Grenier É; Emonnot L; Yara S; Couture P; Beaulieu JF; Ménard D; Seidah NG; Elchebly M
    Atherosclerosis; 2013 Apr; 227(2):297-306. PubMed ID: 23422832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9.
    Geschwindner S; Andersson GM; Beisel HG; Breuer S; Hallberg C; Kihlberg BM; Lindqvist AM; O'Mahony G; Plowright AT; Raubacher F; Knecht W
    Protein Eng Des Sel; 2015 May; 28(5):117-25. PubMed ID: 25744035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.